Double Moving Average Crossover
|Bid||94.61 x 1300|
|Ask||94.71 x 1100|
|Day's Range||93.36 - 95.50|
|52 Week Range||58.67 - 113.32|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||25.84|
|Earnings Date||Aug 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||103.15|
Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.
RALEIGH, N.C., July 02, 2020 -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2020 results after the market closes on Thursday, August 6, 2020. The.
Between 2007-2017, 78 novel adult cancer agents were approved by the U.S. Food and Drug Administration,1 but none of those drugs were researched to determine effectiveness for pediatric cancers. Passed in 2017, the RACE Act amends the existing PREA – Pediatric Research Equity Act – and eliminates the exemption from PREA requirements for cancer drugs that have orphan status. The new law requires pediatric evaluation of new drugs and biologics intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of pediatric cancer.
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service. Users of PRA’s Health Harmony digital platform who enroll in their organization’s COVID-19 Monitoring Program can use the AI-based chatbot, which can recognize and respond to COVID-19-related questions, to enhance their own COVID-19 care. Through a series of conversational questions and interactions within PRA’s Health Harmony digital health platform, the COVID-19 chatbot compares users’ symptoms to U.S. Centers for Disease Control guidance and then recommends one of three available COVID-19 programs in which they should enroll.
In this article we will check out the progression of hedge fund sentiment towards PRA Health Sciences Inc (NASDAQ:PRAH) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 […]
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ladies and gentlemen, thank you for standing by, and welcome to the PRA Health Sciences First Quarter 2020 Earnings Release Conference Call. Good morning, and thank you for joining us for the PRA Health Sciences First Quarter of 2020 Earnings Teleconference. Today, Colin Shannon, our Chief Executive Officer; and Mike Bonello, our Chief Financial Officer, will discuss our quarterly financial results.
Net new business of $604.7 million; Net book-to-bill of 1.10 excluding reimbursement revenueNet new business of $955.9 million; Net book-to-bill of 1.32 including reimbursement.
Those holding PRA Health Sciences (NASDAQ:PRAH) shares must be pleased that the share price has rebounded 33% in the...
RALEIGH, N.C., April 08, 2020 -- PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly.
A Triangle CRO's technology wing has launched a platform allowing for greater patient management for health systems and large employers, which it hopes will help stem the surge of COVID-19 hitting hospitals.
As a response to the ongoing global COVID-19 pandemic, PRA Health Sciences announced today the expansion of its industry-leading Mobile Health Platform for remote clinical monitoring, adding several new capabilities that address sponsor needs for COVID-19 virtual study support. PRA’s Mobile Health Platform (MHP) engages with patients wherever they are. The new capabilities added to address COVID-19 are designed to support clinical trial sponsors and sites participating in clinical studies by allowing them to connect and coordinate with patients who are no longer able to travel to sites due to the current pandemic.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic. The educational program, which provides vital sign tracking, prevention techniques and mental health support for those who are asymptomatic.
Unfortunately for some shareholders, the PRA Health Sciences (NASDAQ:PRAH) share price has dived 38% in the last...
PRA Health Sciences (PRAH) announced today a partnership between Symphony Health and Datavant that expands the breadth of data available for integration and allows life sciences companies to get the deepest and most holistic view of the patient journey in the commercial market. Symphony Health’s proprietary Synoma® de-identification engine enables integration of complementary data sets from across the health ecosystem using a unique token. By leveraging best-in-class de-identification and integration with Symphony Health’s proprietary Synoma engine, customers will be able to connect, expand and analyze all relevant data types – electronic health records, medical and pharmacy claims, diagnostic lab datasets, demographics, and information from patient wearables and sensors collected during clinical trials.
One of Raleigh's largest contract research organizations has reported a year of growth for 2019, including double-digit growth in the fourth quarter, and its executives expect a similar theme in 2020.
Global concerns over the spread of the novel coronavirus rocked stock markets on Monday. The spread of COVID-19 has been a major economic punch felt around the globe, and it's impacting production at Triangle firms – from Lenovo to Cree.
Last week, you might have seen that PRA Health Sciences, Inc. (NASDAQ:PRAH) released its annual result to the market...
Net new business of $658.9 million in the fourth quarter; Net book-to-bill of 1.21$800.2 million of revenue in the fourth quarter; 9.7% growth at actual foreign exchange rates.